

Summary statistics - quantitative results

(Groups: manufacturer of kit)

Filter: minimal size of groups n = 5

EQA round: CRP4/17 - C-Reactive Protein

Dead line: 08.12.2017

| | | |
|------------------------------------------------------|-------------------------------------------------------------------|------------------------------------------|
| RoM = robust average | AV = assigned value | Dmax = acceptable percent difference |
| SD = standard deviation | CRV = certified reference value | LL = lower limit |
| CV = coefficient of variation | RV = reference value | UL = upper limit |
| Ntot = total number of participants | CVE = consensus value from experts | Neva = number of evaluated participants |
| Nout = number of results excluded before calculation | CVP = consensus value from all participants | Nsuc = number of successful participants |
| | CVPG = consensus value from participants groups | Srel = success (relative) |
| | U_{AV} = expanded uncertainty of the assigned value ($k = 2$) | |

| Test | [unit] | Comparability | | | | | Comparability | | | | | | | | |
|---------------------------------|--------|---------------|------|--------|------------------|------------------|----------------------------------------------------------------------------------------|----------|------------------|------|------|------------------|------------------|------------------|-----|
| | | RoM | SD | CV [%] | N _{tot} | N _{out} | AV | U_{AV} | D _{max} | LL | UL | N _{eva} | N _{suc} | S _{rel} | |
| Set of samples 1 | | | | | | | | | | | | | | | |
| (100) C-reactive protein | | | | | 53 | | | | | | | 53 | 50 | 94% | |
| Samples and groups | | [mg/L] | | | | | | | | | | | | | |
| Sample A1 | | 43,5 | 3,1 | 7,2 | 53 | CVP | 43,5 | 1,1 | 24% | 33 | 54 | 53 | 52 | 98% | |
| (1) Abbott | | 44,7 | 1,3 | 3,0 | 9 | 0 | | | | | | 9 | | | |
| (60) Roche | | 41,6 | 2,9 | 6,9 | 19 | 0 | | | | | | 19 | | | |
| (179) Siemens (Bayer) | | 46,3 | 0,15 | 0,32 | 5 | 0 | | | | | | 5 | | | |
| Other | | | | | 20 | 0 | | | | | | 20 | | | |
| | | | | | | | 3x 12, 2x 46, 3x 49, 4x 58, 1x 61, 1x 70, 1x 75, 1x 91, 1x 121, 1x 166, 1x 177, 1x 200 | | | | | | 53 | 50 | 94% |
| Sample B1 | | 27,4 | 2,2 | 8,1 | 53 | CVP | 27,4 | 0,75 | 24% | 20,8 | 34 | 53 | 50 | 94% | |
| (1) Abbott | | 28,4 | 0,85 | 3,0 | 9 | 0 | | | | | | 9 | | | |
| (60) Roche | | 25,9 | 1,6 | 6,1 | 19 | 1 | | | | | | 19 | | | |
| (179) Siemens (Bayer) | | 30,7 | 0,22 | 0,73 | 5 | 0 | | | | | | 5 | | | |
| Other | | | | | 20 | 0 | | | | | | 20 | | | |
| | | | | | | | 3x 12, 2x 46, 3x 49, 4x 58, 1x 61, 1x 70, 1x 75, 1x 91, 1x 121, 1x 166, 1x 177, 1x 200 | | | | | | | | |
| Set of samples 2 | | | | | | | | | | | | | | | |
| (100) C-reactive protein | | | | | 54 | | | | | | | 54 | 52 | 96% | |
| Samples and groups | | [mg/L] | | | | | | | | | | | | | |
| Sample A2 | | 45,2 | 3,8 | 8,4 | 54 | CVP | 45,2 | 1,3 | 24% | 34,3 | 56,1 | 54 | 53 | 98% | |
| (58) Beckman Coulter (Olympus) | | 47,8 | 2,3 | 4,8 | 20 | 0 | | | | | | 20 | | | |
| (60) Roche | | 41,4 | 1,6 | 3,9 | 16 | 0 | | | | | | 16 | | | |
| Other | | | | | 18 | 0 | | | | | | 18 | | | |
| | | | | | | | 4x 1, 2x 12, 4x 49, 4x 149, 2x 178, 2x 179 | | | | | | | | |
| Sample B2 | | 49,5 | 5,3 | 11 | 54 | CVP | 49,5 | 1,8 | 24% | 37,6 | 61,4 | 54 | 52 | 96% | |
| (58) Beckman Coulter (Olympus) | | 53,3 | 2,4 | 4,4 | 20 | 0 | | | | | | 20 | | | |
| (60) Roche | | 44,0 | 2,4 | 5,3 | 16 | 0 | | | | | | 16 | | | |
| Other | | | | | 18 | 0 | | | | | | 18 | | | |
| | | | | | | | 4x 1, 2x 12, 4x 49, 4x 149, 2x 178, 2x 179 | | | | | | | | |

st_kn_p

End of report

Printed: 14.12.2017